Author Archives: Paul Samuel

GlycoMimetics-Pfizer accord pays off

GlycoMimetics Inc., of Gaithersburg, a biopharmaceutical company focused on discovering and developing drugs for human wound healing and tissue repair, said it has received a $15 million payment from Pfizer Inc., under a collaborative agreement between the two companies for the development of rivipansel, a treatment for painful episodic flare-ups of sickle cell disease.

Read More »

EntreMed reports higher loss in 1Q

EntreMed Inc., of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, reported financial results for the three months ended March 31, 2014.

Read More »

OpGen launches microbe detection test

OpGen Inc., of Gaithersburg, a molecular diagnostics provider, said it has developed a new test that can quickly and reliably identify patients at risk for harboring serious disease-causing microbes that can resist even the strongest antibiotics.

Read More »

Cannabis component eyed as cancer drug

Nuvilex Inc. said it signed a research agreement with the University of Northern Colorado to perform initial studies in the development of cancer treatments that utilize components of cannabis known as cannabinoids.

Read More »

Heinz executive hired by McCormick

A top-level executive at H.J. Heinz Co. has been named president of U.S. Consumer operations at McCormick & Co. Inc., the Sparks-based spice and food flavorings company announced Thursday.

Read More »